01. Innovations and models of financing to improving diagnostic services under the East Africa Laboratory Project

Thursday, 30 October 2014, 17:00 - 18:30
Room 111

Type: Sponsored Satellite Symposium
Track: Tuberculosis
Topic: Public policy
Organised by: East, Central and Southern Africa Health Community

Description:
This session will share an innovative conceptual framework developed for assessing the economic and health impact of investing laboratories; share lessons learnt from implementation of performance-based financing in accelerating laboratory quality improvement; present options for promoting public-private partners; and highlight results from the introduction of new technologies in improving diagnostic services and opportunities in public-private partnerships to support laboratory services delivery in the region.

Target audience: Infectious disease experts, senior MOH officials, TB programme managers, key policy-makers, development partners, and representatives of civil society organisations.

Objectives:
1. Share conceptual framework for assessing the economic and health impact of investing in laboratories
2. Present results from the application of performance-based financing related to laboratories
3. Explore potential public-private partnerships in support of laboratory service delivery in the region
4. Discuss impact of new technologies in resource-constrained settings in cross border areas

Keywords: Tuberculosis

Coordinator(s): Martin Matu (Tanzania, United Rep.)
Chair(s): Miriam Schneidman (USA)

Presentations:
17:00 - 17:15 Overview of the EAPHLNP
   Miriam Schneidman (USA)
17:15 - 17:30 Conceptual framework for evaluating economic and health impact of investing in laboratories
   Anna Krivelyova (USA)
17:30 - 17:45 Experiences on implementation of performance-based financing to accelerate laboratory accreditation
   Claver Kayobotsi (Rwanda)
17:45 - 18:00 Early lessons derived from a study to explore the impact of new diagnostics in TB diagnosis
   Willie Githui (Kenya)
18:00 - 18:15 Opportunities for public-private partnerships in supporting laboratory service delivery in the region
   Martin Matu (Tanzania, United Rep.)
18:15 - 18:30 Discussion
02. Expansion of M/XDR-TB programmatic management in the Russian Federation

Thursday, 30 October 2014, 17:00 - 18:30
Room 113

Type: Sponsored Satellite Symposium
Track: Tuberculosis
Topic: Medical management of TB and drug resistant TB
Organised by: Regional public organization for the disabled people (RPODP) “Human Health”, Russia

For the past few years the Russian Federation has been demonstrating significant decreasing of TB notification and TB mortality rates. However, increasing rates of M/XDR-TB is a remaining challenge for TB control in the country. The overall aim of the programme is to present modern approaches to TB control and national best practices focused on effective M/XDR-TB management.

Target audience: NTP managers, TB consultants, TB specialists, TB laboratory specialists.

Objectives:
1. To share experiences and best practices of M/XDR-TB management in a MDR-TB high-burden country
2. To discuss challenges and opportunities for improvement of M/XDR-TB management in the Russian Federation.

Keywords: Tuberculosis; MDR-TB; XDR-TB; PMDT; TB laboratory diagnosis

Coordinator(s): Vadim Testov (Russian Federation)
Chair(s): Teresa Kasaeva (Russian Federation), Irina Vasilyeva (Russian Federation)

Presentations:
17:00 - 17:15 M/XDR-TB: the challenges for TB control in the Russian Federation
   Irina Vasilyeva (Russian Federation)
17:15 - 17:30 Diaskin-test: new variation of TB skin test
   Ludmila Slogotskaya (Russian Federation)
17:30 - 17:45 New national laboratory algorithm for TB detection, diagnostic and DST
   Larisa Chernousova (Russian Federation)
17:45 - 18:00 MDR-TB treatment outcomes in the Russian Federation
   Vadim Testov (Russian Federation)
18:00 - 18:15 Treatment of M/XDR-TB: challenges and new opportunities
   Anastasia Samoilova (Russian Federation)
18:15 - 18:30 MSF activities for PMDT implementation in the North Caucasus, Russia Federation [example of collaboration]
   Animesh Sinha (Netherlands)
Session N.00292

**03. Streamlining treatment for drug-resistant TB: market approaches for better TB care**

**Thursday, 30 October 2014, 17:00 - 18:30**  
**Room 114**

**Type**  
Sponsored Satellite Symposium

**Track**  
Tuberculosis

**Topic**  
Medical management of TB and drug resistant TB

**Organised by**  
UNITAID

**Description**  
A wide range of treatment options exist with the use of around 20 drug-resistant TB medicines. While some variation is vital, other options may be clinically unnecessary. This complicates TB care and fragments an already small market, leading to supply shortages and high prices. Simpler, shorter TB treatment could foster healthier markets, better enabling appropriate TB medicines to be provided to people who urgently need them. But evidence is needed to inform effective use of new and existing medicines. This session will explore market trends and potential impact of streamlining drug-resistant TB treatment.

**Target audience**  
Many stakeholders have an interest in understanding needs and likely evolution of TB medicines markets, including implementers, governments, donors, international organisations, regulators, policy-makers, civil society, academics, and industry.

**Objectives**

1. Review the urgent need for shorter, safer, effective drug-resistant TB treatment
2. Examine the TB landscape to understand the potential impact of streamlined treatment
3. Describe tangible first steps in transforming markets for drug-resistant TB treatment
4. Discuss further strategies to improve drug-resistant TB care through market approaches

**Keywords**

Access; MDR-TB; medicines; innovation; markets; tuberculosis

**Coordinator(s)**

Janet Ginnard (Switzerland), Katherine Blumer (Switzerland)

**Chair(s)**

Brenda Waning (Switzerland), Carol Nawina Nyirenda (Zambia)

**Presentations**

17:00 - 17:15 Perspectives from the community: the need for shorter, safer effective drug-resistant TB treatment  
Dalene Von Delft (South Africa), Thato Mosidi (South Africa)

17:20 - 17:35 Insights from the TB medicines landscape: pre-conditions for new drugs impact  
Carmen Perez Casas (Switzerland)

17:40 - 17:55 Priority drug-resistant TB regimens: improving the knowledge base to transform the market  
Michael Rich (USA)

18:00 - 18:15 Further strategies to consolidate demand: addressing non-essential variation and other opportunities  
Regina Osih (South Africa)

18:20 - 18:30 Discussion
04. A rights-based approach: the key to zero TB and HIV infections

Thursday, 30 October 2014, 17:00 - 18:30

Type: Sponsored Satellite Symposium
Track: Civil Society
Topic: Advocacy and human rights

Organised by: UNAIDS & Stop TB Partnership

Description:
TB is a disease that is perpetuated by inequality. It affects key vulnerable populations (women, prisoners, children, migrants, mobile populations, people with disabilities including mental health and people who use drugs). Most of these people have minimal access to basic services and human rights literacy programmes. The use of a rights-based approach to managing TB requires the involvement of the community to ensure sustainability of any interventions. Strategies on how to replicate these community-driven responses and strengthen the involvement of the community will be discussed.

Target audience:
People affected by HIV and TB, activists, national TB and HIV programme managers, lung health specialists, clinicians, lawyers, epidemiologists, international consultants, laboratory scientists, microbiologists, judicial officials.

Objectives:
1. Demonstrate link between HIV, TB and the need to utilise a rights-based approach and promote patients rights
2. Share success stories from countries that have used a rights-based approach to address TB violations

Keywords:
Human rights; rights-based; policies; TB/HIV; treatment; prevention; detention; judicial; vulnerability; civil society; community members

Coordinator(s):
Allan Malleche (Kenya), Jennifer Dietrich (Switzerland)

Chair(s):
Grover Anand (India), Clayton Michaela (Namibia)

Presentations:
17:00 - 17:10 Welcome from the chairs and opening remarks from Meg Davis
17:10 - 17:20 Using the rights-based approach to develop community-driven solutions for patients who have discontinued their treatment
17:20 - 17:30 Working with communities in a rural setting: using a rights-based approach within the Eastern Cape
17:30 - 17:40 Reforming the century-old compensation system for occupational lung disease in the South African mining sector
17:40 - 17:50 How can activists influence policy change: example of migrants suffering TB deportation in Asia
17:50 - 18:00 Lawsuits at the Inter-American Court on Human Rights to guarantee access to health
18:00 - 18:10 Ending suffering and discrimination in HIV/TB
18:10 - 18:30 Q&A and discussion
The symposium will focus on advancements in clinical research for MDR-TB in adults and children and profile the Young Innovator in TB Research Award winner. Questions to be addressed: following regulatory approval of two new MDR-TB medicines, what can be done to ensure responsible access? What are the challenges of conducting MDR-TB trials in children? Dr Wiel de Lange, University Medical Center Groningen, will provide an overview of the MDR-TB drug development landscape. Dr Lawrence Geiter, Otsuka, will provide an update on delamanid clinical development, including safety/efficacy data for XDR-TB. Dr Melchor Frias, De La Salle Health Sciences Institute, will present new research on dosing for paediatric MDR-TB patients. Dr Francis Drobniewski, Imperial College London, will conclude with how these new tools can be successfully implemented in a programmatic context.

Target audience: Scientists, researchers, public health representatives, advocates and others involved in TB care and control.

Objectives:
1. Present progress on the development and implementation of new anti-TB compounds
2. Share the latest available clinical data on delamanid research and impact on XDR-TB sub-populations
3. Provide an overview of the challenges and progress in facilitating clinical trials for MDR-TB in children

Keywords: MDR-TB; trials; children

Coordinator(s): Marc Destito (Switzerland)

Chair(s): Wiel de Lange (Netherlands)

Presentations:
17:00 - 17:10 Welcome and introduction
Wiel de Lange (Netherlands)

17:10 - 17:35 Delamanid for multidrug-resistant tuberculosis (MDR-TB)
Lawrence Geiter (USA)

17:35 - 17:55 Conducting early drug development trials in children with MDR-TB
Melchor Frias (Philippines)

17:55 - 18:15 Two new TB drugs: what more do we need?
Francis Drobniewski (UK)

18:15 - 18:30 Refreshments and discussion with Global Winner of 2014 Young Innovator in TB Research Award
Current health challenges can only be overcome when a wide array of stakeholders work together to conduct operational research that illuminates effective solutions. But this also requires an understanding of operational research concepts and techniques. Because stakeholders frequently lack the time and resources needed to attend traditional face-to-face courses, TREAT TB has developed an approach to web-based learning that provides stakeholders with the knowledge and training they need to conduct high-quality and programmatically-relevant operational research.

Policy-makers, health professionals, government officials, major donors and others interested in operational research.

1. Demonstrate how new technology can bring high-quality operational research training to health professionals
2. Explain how complex technical subjects can be mastered using interactive software.

TB; operational research; global health.

Tara Ornstein (USA)

Ya Diul Mukadi (USA), Lynne Franco (USA)

<table>
<thead>
<tr>
<th>Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 17:15 Virtual OR Training: early experiences within the TREAT TB Initiative I. D. Rusen (Canada)</td>
</tr>
<tr>
<td>17:15 - 17:30 Pulmonary TB contact tracing in a priority municipality for disease control in Brazil Anneliese Wysocki (Brazil)</td>
</tr>
<tr>
<td>17:30 - 17:45 Which combination of the six tuberculosis screening questions predicts sputum smear which highest accuracy Stephen Kisorio (Kenya)</td>
</tr>
<tr>
<td>17:45 - 18:00 Early anti-retroviral therapy initiation of MDR-TB and HIV co-infected patients in Swaziland Janet Ongole (Swaziland)</td>
</tr>
<tr>
<td>18:00 - 18:15 Factors associated with unsuccessful treatment outcomes of MDR-TB patients in Tamil Nadu state, India Sree T. Sucharitha (India)</td>
</tr>
<tr>
<td>18:15 - 18:30 Discussion</td>
</tr>
</tbody>
</table>
Paediatric TB is one of the top causes of death in children worldwide. The lack of appropriate medicine has contributed to this problem, however the market for paediatric TB medicines is finally changing, with important recent progress. This session presents new data to clarify the size and dynamics of the paediatric TB drug market; provides updates on progress to bring new, child-friendly formulations of both existing and new drugs to the field; and offers perspectives on how to maximise uptake, improving children’s access to appropriate, affordable, quality TB medicine.

Target audience
NTP managers, health programme managers and policy-makers, specialists and agencies providing technical assistance, manufacturers, donors, paediatricians.

Objectives
1. Present new market research data to clarify the volume and dynamics of the current paediatric treatment market
2. Provide update on progress of current efforts to make paediatric drugs in the correct dosages
3. Discuss strategies to ensure maximum uptake of new paediatric treatments coming to market
4. Offer overview of new treatments in development and their potential impact

Keywords
Paediatric TB; market dynamics; formulations; dosage; product introduction; policies; clinical trials

Coordinator(s)
Joanna Breitstein (USA), Janet Ginnard (Switzerland)

Chair(s)
Phillipe Duneton (Switzerland), Clemax Sant Anna (Brazil)

Presentations
17:00 - 17:10 Market understanding: new data on the purchasing habits of 22 high-burden countries
Cherise Scott (USA)

17:10 - 17:15 Market understanding: new data on the purchasing habits of 22 high-burden countries
Cherise Scott (USA)

17:15 - 17:25 Progress and challenges in optimising and delivering new paediatric products
Vijay Agarwal (India)

17:25 - 17:30 Finding the most neglected: identifying and treating more children with TB
Dyah Mustikawati (Indonesia)

17:30 - 17:40 Finding the most neglected: identifying and treating more children with TB
Dyah Mustikawati (Indonesia)

17:40 - 17:45 Strategies to promote uptake of appropriately formulated paediatric TB drugs
Malgorzata Grzemska (Switzerland)

17:45 - 17:55 Strategies to promote uptake of appropriately formulated paediatric TB drugs
Malgorzata Grzemska (Switzerland)

17:55 - 18:00 Tomorrow’s treatments: outlook for the paediatric TB drug pipeline
Anneke Hesseling (South Africa)

18:00 - 18:10 Tomorrow’s treatments: outlook for the paediatric TB drug pipeline
Anneke Hesseling (South Africa)

18:10 - 18:15 Discussion
In October 2012, the Ethiopian government with key national and international partners launched a multiyear initiative to build sustainable capacity for operational research (OR) funded under the USAID TB CARE I initiative with the aim to develop strong technical capacity at national and regional levels to enhance the use of TB research for evidence based TB control. Using a “learning by doing approach” and a local mentorship programme, new capacity was built and existing capacity enhanced. During this symposium the OR initiative and results of OR projects conducted will be presented focusing on the impact on TB control and how to continue building sustainable OR capacity.

Target audience
TB researchers, policy-makers and representative of national TB programmes who like to learn how operational research capacity can successfully be build.

Objectives
1. To share experience on sustainable operational research capacity building
2. To share result of OR projects conducted under the Ethiopian OR initiative and their implications for TB control
3. To discuss best practices and way forward in building sustainable operational research capacity that is used to improve programme performance

Keywords
Operational research

Coordinator(s)
Dawit Assefa Lemma (Ethiopia), Eveline Klinkenberg (Ethiopia)

Chair(s)
Andargachew Kumsa (Ethiopia), Abraham Aseffa (Ethiopia)

Presentations
17:00 - 17:10 Overview of the Ethiopia OR initiative
Dawit Assefa Lemma (Ethiopia)

17:10 - 17:20 Centralised versus decentralised tuberculosis care: the case of Oromia Region, Ethiopia
Kassa Hailu (Ethiopia)

17:20 - 17:30 A quarter of health centers had poor symptomatic tuberculosis screening practice in Amhara region, Ethiopia
Gebremedhin Gebregergs (Ethiopia)

17:30 - 17:40 Opportunities and challenges in the management of MDR-TB patients in the treatment follow-up centers in Addis Ababa
Daniel Fiseha Adhana (Ethiopia)

17:40 - 17:50 Factors associated with case notification of smear-positive TB in Southern Nations, nationalities and Peoples’ Region
Tarekegn Solomon (Ethiopia)

17:50 - 18:00 Building sustainable capacity for operational research, lessons learnt and the way forward
Eveline Klinkenberg (Ethiopia)

18:00 - 18:30 Roundtable discussing the best approach to build OR capacity
**Session N.00471**

09. Responding to MDR-TB from the ground up: case studies on community-driven solutions

**Friday, 31 October 2014, 17:00 - 18:30**

**Room 120/121**

**Type**
Sponsored Satellite Symposium

**Track**
Tuberculosis

**Topic**
Medical management of TB and drug resistant TB

**Organised by**
The Lilly MDR-TB Partnership

**Description**
This session showcases creative, effective and low-cost solutions to improving MDR-TB treatment outcomes. Experience shows supporting people on treatment at the one-on-one level improves treatment success rates. This session highlights models that can be easily replicated: collaborating with religious groups and traditional medicine in China; building pharmacist and rural healthcare provider capacity as community support in India; developing a sustainable approach for groups at greatest risk of loss to follow-up in Russia; strengthening the support web by partnering with government in South Africa; and tipping the scales on treatment outcomes through small investments in social support.

This session is targeted to a broad audience interested in MDR-TB. This may include civil society organisations, advocates, policy-makers, national TB programme staff, researchers, donors, health care professionals, national and international partners.

**Objectives**
1. To illustrate concrete examples of models which address MDR-TB in a variety of community-based settings
2. To share implementation of lessons learnt
3. To enhance MDR-TB care and outcomes through community-based approaches

**Keywords**
MDR-TB

**Coordinator(s)**
Amy Israel (Switzerland)

**Chair(s)**
Evan Lee (Switzerland), Eliud Wandwalo (Switzerland)

**Presentations**

17:00 - 17:05 Welcome
Evan Lee (Switzerland)

17:05 - 17:10 Setting the stage: the need for community-based solutions in addressing MDR-TB
Eliud Wandwalo (Switzerland)

17:10 - 17:20 Strengthening community engagement: working with religious groups, media and traditional medicine in China
Yong Cheng Ma (China)

17:20 - 17:30 Tapping into a cadre of community based pharmacists and rural healthcare providers to tip the scales in India
Vikas Panibatla (India)

17:30 - 17:40 Replicating the Sputnik model to reach groups at greatest risk in Russia
Salmaan Keshavjee (USA)

17:40 - 17:50 Connecting community with follow up in the Eastern Cape, South Africa: clinics, homes, schools and prisons
Mike Brunt (South Africa)

17:50 - 18:00 Improving adherence one individual at a time: lessons from the Red Cross approach
Lasha Goguadze (Switzerland)

18:00 - 18:30 Panel discussion